Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

Form 144

144: Issuer Information

Name of Issuer
Ligand Pharmaceuticals Inc
SEC File Number
001-33093
Address of Issuer
3911 Sorrento Valley Blvd
Suite 110
San Diego
CALIFORNIA
92121
Phone
8585507500
Name of Person for Whose Account the Securities are To Be Sold
John W. Kozarich
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer
  1. Board of Directors

144: Securities Information


RecordTitle of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
#1Common Stock
UBS Financial Services Inc
1000 Harbor Blvd
3rd Floor
Weehawken
NEW JERSEY
07086
4,444$343,076.8017,273,00005/16/2023
NASDAQ

144: Securities To Be Sold

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

RecordTitle of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
#1Common05/11/2021stock option exercisestock option exercise from issuer☐ — 4,44405/11/2021cash


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

144: Securities Sold During The Past 3 Months

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

RecordName and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
#1John W. Kozarich
501 West Ave
Apt 2901
Austin
TEXAS
78701		common stock05/08/20236,408$490,627

144: Remarks and Signature

Remarks
John W. Kozarich is the Affliate, he is a co-trustee of the Kozarich-Durso Living Trust DTD 01/13/1996
Date of Notice
05/16/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature
/s/ UBS Financial Services Inc, as attorney-in-fact for John W. Kozarich

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Ligand Pharmaceuticals (NASDAQ:LGND)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse Ligand Pharmaceuticals
Ligand Pharmaceuticals (NASDAQ:LGND)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse Ligand Pharmaceuticals